drugset / Trial / NCT03022045

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT03022045

Phase 3 Completed 18 enrolled AbbVie
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

Timeline

Start
2017-01-26
Primary completion
2017-09-17
Completion
2020-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Risankizumab Monoclonal antibody 75 mg Subcutaneous
Subject Risankizumab Monoclonal antibody 150 mg Subcutaneous

Indications